ABSTRACT – Background: The carcinoembryonic antigen level in peritoneal lavage has been showing to be a reliable prognostic factor in gastric cancer. Aim: To identify any association between carcinoembryonic antigen level in peritoneal lavage, in gastric cancer patients, with mortality, peritoneal recurrence, tumor relapse or other prognostic factors. Methods: In total, 30 patients (22 men, 8 women; median age 66 years) with resectable gastric cancer (mainly stage III and IV) were studied. Carcinoembryonic antigen level in peritoneal lavage was detected at operation by immunocytochemical method and a level over 210 ng/g of protein was considered as positive. Results: There were detected 10 positive cases (33.3%) of pCEA levels. These levels were associated with mortality, RR: 2.1 (p=0.018); peritoneal recurrence, OR: 9.0 (p=0.015); and relapse or gastric cancer progression, OR: 27.0 (p<0.001). Conclusion: Increased levels of pCEA fairly predicts mortality, peritoneal recurrence tumor relapse or cancer progression.
to 20% with macroscopic peritoneal involvement present a negative cytology.

Due to the low sensitivity of conventional cytology, other techniques searching for antigens produced by neoplastic cells have been studied, with the purpose of increasing peritoneal lavage sensitivity.

Carcinoembryonic antigen levels in peritoneal lavage (plCEA) have shown to be good postoperative mortality indicator in serosa-involved gastric cancers, even in those cases without visible peritoneal carcinomatosis during surgery.17,4,3,22

Abe et al found positive association between elevated plCEA and serosa invasion. Its elevated levels were independent predictors of gastric cancer mortality and peritoneal recurrence.19 Wang et al showed the same results in peritoneal recurrence.20 Only plCEA levels were a significant predictor of mortality in another study. Among patients with peritoneal recurrence, 95% showed positivity.3 Regardless of the study method used, plCEA levels play an important role as prognostic predictors in gastric cancer patients.

Due to elevated prevalence and the possibility of finding other prognostic factors that could interfere and help on the treatment and survival of patients, peritoneal lavage CEA levels will be measured, analyzing their relation or interference on six month mortality, peritoneal recurrence or general survival, in gastric cancer patients.

METHODS

This project was correctly evaluated and approved by the Hospital’s research Ethics Committee, and patients were asked to assign an informed consent.

Patients with gastric cancer submitted to surgical resection, regardless of the tumor stage, by the general surgery staff at the Hospital São Lucas, Pontifical Catholic University of Rio Grande do Sul, Porto Alegre, RS, Brazil. Were included only the ones that underwent primary tumor resection and peritoneal lavage with adenocarcinoma tumors. The excluding cases were those with urgent indication of surgery that had no proper time for tumor diagnosis or peritoneal lavage; patients with another concomitant digestive cancer, or tumor recurrence after resection surgery.

At the end of the peri-operative period, after laparotomy, 200 ml of physiological saline was introduced into the rectovaginal or the rectovesical spaces; after a manual lavage 20 ml of it was collected for conventional cytology study. Other 20 ml were collected for total protein and CEA levels measuring. The CEA levels were determined with a radiometric immunoassay kit and expressed as ng/g of protein. plCEA levels ≥210 ng/g of protein were defined as positive.

Demographic information, cancer stage pre and post-surgery, comorbidity, signs and symptoms, targeted therapy, disease evolution, and treatment response were evaluated. The patients were follow-up until these study end or death.

Statistical analysis

All were done with SPSS statistics software. The $\chi^2$ test was used to analyze the association between the variables. It was used logistic regression to analyze the significate variables in $\chi^2$ test. The survival rate was calculated by Kaplan-Meier method and statistical difference was evaluated by long-rank test.

The calculated sample size was 60 gastric cancer patients, considering a mean survival rate of 30% in patients with positive plCEA, which was 10% smaller than overall survival in current literature in a six month period. It was considered as significant a 95% confidence interval and statistic power of 80%.

RESULTS

Thirty patients with gastric cancer were evaluated, 22 men and eight women, with a median age of 66 years (42-97). They were followed-up in a mean time of 17.43 months (0-46).

Tumor characteristics are shown on Table 1. Distant metastases were found in 23.3%, from which 57% deceased before being discharged from the hospital. The peritoneal levels of CEA were between 25 ng/g to 21,200 ng/g, with a median of 157.5 ng/g. Peritoneal levels of CEA ≥210 ng/g were found in 33.33% of patients.

### TABLE 1 - Tumor characteristics of patients with gastric cancer (n=30)

| Characteristics          | n (%) |
|--------------------------|-------|
| Serosa invasion (T3 ouT4) | 25 (83.3) |
| Lymph node’s involvement (N1-3) | 20 (66.7) |
| Distance metastasis (M1)   | 7 (23.3)  |
| Clinical stage IV          | 12 (40)   |
| Positive cytology          | 2 (6.7)    |
| Positive plCEA             | 10 (33.3)  |

During the follow-up period 37.6% had cancer relapse, and in 63.6% of them, the peritoneal recurrence was the first kind of relapse. The recurrence in six month was 23.3% (Table 2).

### TABLE 2 - Recurrence in patients with gastric cancer

| Recurrence                              | n (%) |
|-----------------------------------------|-------|
| Recurrence in six months                | 7 (23.3) |
| Total recurrence                         | 11 (36.7) |
| Peritoneal recurrence                    | 7 (23.3) |
| Recurrence or gastric cancer progression | 14 (46.7) |

The factors related to elevated plCEA were T4 stage (p=0.015), involvement of lymph nodes (p=0.006), positive cytology (p=0.038) and stage grouping IV (IV SG) (p=0.002, Table 3).

### TABLE 3 - Factors related to elevated plCEA

| Factors                   | Statistical significance |
|---------------------------|--------------------------|
| Positive cytology         | p=0.038                  |
| Involvement of lymph nodes| p=0.006                  |
| T4 stage                  | p=0.015                  |
| IV SG                     | p=0.002                  |

The plCEA levels were the only risk factor to peritoneal recurrence, with OR: 9 (1.325 – 61.138) 95CI, p= 0.015.

Positive plCEA levels, involvement of lymph nodes, IV SG, T4 stage, distant metastases, residual disease, extended lymphadenectomy not performed, and lack of adjuvant treatment were risk factors for tumor relapse or disease progression. The plCEA levels ≥210 ng/g were the only independent risk factor for tumor relapse or disease progression (Table 4).

Was found 30% mortality in a six month period, which correlated with positive plCEA levels, residual disease and lack of adjuvant therapy (Table 5). The overall survival was 36.7%, significantly lower in patients with positive plCEA levels (Figure 1). Regarding to overall mortality, positive plCEA levels, resection without extended lymphadenectomy, distant metastases, lymph node involvement, T4 stage, IV SG and lack of adjuvant therapy were correlated factors (Table 5). In concern to disease mortality during follow-up, the related factors were positive plCEA levels OR: 12 (1.885 – 76.376)95 IC, lymph node involvement OR: 13.5 (1.421 – 128.258)95 IC, T4 stage OR: 13.714 (1,381 – 136,212)95 IC and IV SG OR: 10.5 (1.885 – 58.359)95 IC.
TABLE 4 - Factors related to recurrence or disease progression

| Factors                                | Univariate analysis                        | Logistic regression                        |
|----------------------------------------|--------------------------------------------|--------------------------------------------|
| plCEA                                  | OR: 27 (2.705 – 269.460)IC                 | OR: 38.206 (1.075 – 1358.419)IC             |
| Lymph nodes involvement                | OR: 16.714 (1.742 – 160.350)IC              | NS*                                        |
| T4 stage                               | OR: 11.25 (1.146 – 110.461)IC               | NS*                                        |
| Distant metastases                     | OR: 11.25 (1.146 – 110.461)IC               | NS*                                        |
| IV stage grouping                      | OR: 17.5 (2.667 – 114.846)IC               | NS*                                        |
| Residual disease                       | RR: 1.4 (1.005 – 1.959)IC                  | NS*                                        |
| Extended lymphadenectomy not performed | OR: 5.4 (1.120 – 26.044)IC                 | NS*                                        |
| Adjuvant therapy not performed         | OR: 6 (1.003 – 35.908)IC                   | NS*                                        |

*Not significant

TABLE 5 - Factors related to mortality

| Factors                                | Mortality in six months | General mortality |
|----------------------------------------|-------------------------|-------------------|
|                                        | Univariate analysis     | Logistic regression | Univariate analysis | Logistic regression |
| plCEA                                  | OR: 8.5 (1.458 – 49.539)IC 95% | NS* | RR: 2.111 (1.314 – 3.391)IC 95% | NS* |
| Residual disease                       | RR: 1.8 (1.003 – 3.229)IC 95% | NS* | NS* | NA** |
| Lymph node involvement                | NS*                      | NA** | OR: 9.333 (1.637 – 53.208)IC 95% | NS* |
| Stage T4                               | NS*                      | NA** | RR: 1.583 (1.123 – 2.232)IC 95% | NS* |
| IV SG                                  | NS*                      | NA** | RR: 2.714 (1.507 – 4.890)IC 95% | NS* |
| Distant metastases                     | NS*                      | NA** | RR: 1.583 (1.123 – 2.232)IC 95% | NS* |
| Extended lymphadenectomy               | NS*                      | NA** | OR: 6.188 (1.041 – 36.779)IC 95% | NS* |
| Lack of adjuvant therapy               | RR: 1.818 (1.223 – 2.703)IC 95% | NS* | OR: 22.667 (3.140 – 163.629)IC 95% | NS* |

*No significance **Not available

The importance of this study is related to the current need to find, among gastric cancer patients, the ones with worse prognostic factors, so they can be provided with an appropriate adjuvant therapy.

We found results similar to previous studies, showing a positive association between elevated plCEA levels and tumor recurrence and mortality in patients who underwent tumor resection. What’s more, this is the first western study to confirm these results, probably because we used the same methods and cut points of previous studies.

Some researchers have not found any relation between plCEA levels and peritoneal recurrence or survival, but their peritoneal washing technique included at least 500 ml saline solution with no correction by protein levels. So, it is difficult to compare their findings to ours or to others that used plCEA levels in ng/g of protein.

We also found plCEA positive levels in a higher percentage compared to studies which used a similar cut point, probably because our patients had more advanced tumor stages. This enforces the fact that there are other important prognostic factors beyond the already well-established ones, which are vital to define the kind of treatment offered, especially to advanced tumor patients.

In the multivariate analysis these findings didn’t show statistical significance, probably because the number of patients was not enough to differentiate groups.

Although was not reached initial number, was found statistical significance in relation to mortality in a six month period, probably because the great difference in death rate between groups, being 60% in plCEA >210 and 15% in plCEA <210 ng/g.

Even with such a small number, the mortality difference between groups cannot be ignored, being 80% in plCEA positive and 25% in plCEA negative patients during disease follow-up, and 90% vs. 45% overall mortality, respectively. Neither can we randomly attribute these differences to the fact that patients with T4 stage with lymph node involvement or IV SG have positive plCEA levels, since our number of patients was not enough to distinguish groups.

We should, however, analyze and compare our results with others in current literature, considering plCEA levels as an important risk factor to peritoneal recurrence and mortality.

Possible reasons for peritoneal recurrence could be either the existence of cancer cells in the abdominal cavity due to gastric wall invasion prior to surgery or the release of neoplastic cells by lymph vessels sectioned during surgery, or even by iatrogenic dissemination caused by the surgical act itself. The presence of cancer cells in peritoneal cavity, that produce CEA, but are not detected by conventional cytology, could explain the relation between plCEA levels and peritoneal recurrence.

The most reliable hypothesis for elevated CEA levels in peritoneal wash is that cancer cells produce a sufficient amount of CEA to be detected. This could explain the correlation between CEA peritoneal levels and T4 stage, but not the association with lymph node involvement.

Another mechanism would be the liberation of elevated CEA levels in the peritoneal cavity by elevated blood levels of CEA.

To define whether CEA levels are produced by neoplastic cells inside the peritoneal cavity or by the primary tumor, more accurate studies involving this issue are needed. However, we should at least consider the possibility that plCEA levels are more sensitive than conventional cytology to detect neoplastic cells or to determine the risk of peritoneal recurrence.

In this study tumor invasion of other organs and positive
cytology were linked to elevated CEA levels, a finding that could correlate wall invasion with plCEA levels. However, other factors associated to plCEA, like lymph node involvement and IV SG, are not necessarily related with invasion depth. Besides, we haven’t found any relation between T3 stage and elevated CEA levels. Consequently, we don’t have enough evidence-based data to speculate the mechanisms involved with elevated CEA levels in the peritoneal cavity.

Most of the patients diagnosed with gastric cancer that undergo surgical resection in western countries show more advanced stages of the disease and hence worse survival rates, which reinforces the need to use other prognostic factors as well as new therapies to offer them.

Peritoneal lavage levels of CEA were discovered a couple of years ago and are being used as indicators of peritoneal recurrence, one of the most common kinds of tumor relapse. In this study elevated plCEA levels were the only significant prognostic factor for developing peritoneal recurrence, as well as the only risk factor for relapse or disease progression in multivariate analysis.

The peritoneal wash is undertaken in the beginning of the surgery, before tumor manipulation, being the results available within 1-3 h depending on the method, resulting in information that can influence the decision of therapeutic options.

Forthcoming studies will probably search the utilization of new therapies specifically developed to avoid peritoneal recurrence (such as transoperative chemotherapy) in patients more susceptible to this kind of recurrence (like the ones with elevated plCEA levels).

While new therapies are not yet well-established, plCEA levels can be helpful to decide whether performing extended lymphadenectomy during surgery or postoperative chemotherapy and radiotherapy.

Bringing to a close, the results shown suggest that the use of carcinoembryonic antigen level in peritoneal lavage does determine and may be used as a reliable predictive factor of worst prognosis, resulting on a useful tool when deciding for the best and most accurate treatment.

CONCLUSIONS

Elevated CEA levels are significantly associated with a higher mortality rate inside the first six months after resectional surgery. They are also directly related to lymph involvement, transmural invasion and an advance clinical stage. Higher levels of CEA are greatly associated with general mortality and disease-related mortality, as well as tumor progression and tumor recurrence. It is important to take into consideration that the increase of CEA levels in peritoneal lavage is the only significant factor associated with peritoneal recurrence.

REFERENCES

1. Abe N, Watanabe T, Toda H, Machida H, Suzuki K, Masaki T, Mori T, Sugiyama M, Tatomori N, Nakaya Y. Prognostic significance of carcinoembryonic antigen levels in peritoneal washes in patients with gastric cancer. Am J Surg 2001 Apr; 181(4): 356-361.
2. Abe S, Yoshimura H, Tabata H, et al. Curative resection of gastric cancer: limitation of peritoneal lavage cytology in predicting the outcome. J Surg Oncol 1995; 59: 226-229.
3. Asao T, Fukuda T, Yazawa S, Nagomachi Y. Carcinoembryonic antigen levels in peritoneal washings can predict peritoneal recurrence after curative resection of gastric cancer. Cancer 1991; 68: 44-47.
4. Asao T, Fukuda T, Yazawa S, Yazawa Y. CEA levels in peritoneal washings from gastric cancer patients: prognostic guide. Cancer Lett 1989;47: 79-81.
5. Bando E, Yonemura Y, Takeshita Y, Taniguchi K, Yasui T, Yoshimitsu Y, Fushida S, Fujimura T, Nishimura G, Miwa K. Intraoperative lavage for cytological examination in 1297 patients with gastric carcinoma. Am J Surg 1999; 178: 256-262.
6. Bonenkamp JJ, Sogun I, Hermans J, van de Velde CJ. Prognostic value of positive cytology findings from abdominal washings in patients with gastric cancer. Br J Surg 1996; 83: 672-674.
7. Broll R, Duchrow M et al. Prognostic significance of free gastrointestinal tumor cells in peritoneal lavage detected by immunocytochemistry and polymerase chain reaction. Langenbeck’s Arch Surg. 2001 Mar; 285-292.
8. Kodama Y, Yamamura Y, Tosi A, Uesaka K, Hirai T, Yatsu T, Morimoto T, Kato T, Kito T. Prospective staging of gastric carcinoma. A comparison between the UICC stage classification and the 12th edition of the Japanese General Rules for Gastric Cancer Study. Scand J Gastroenterol 1996;31: 476-480.
9. Li J, Zheng M, Miao CW, Zhang JH, Ding QG, Wu WS. Peritoneal lavage cytology and carcinoembryonic antigen determination in predicting peritoneal metastasis and prognosis of gastric cancer. World J Gastroenterol 2005; 11(46): 7374-7377.
10. Mandowskivi S, Lourenço LG, Forones NM. CA 72-4 e no soro e no lavado peritoneal de doentes com cancer gastrointestino. Arq Gastroenterol 2002; 39(1): 17-21.
11. Moriguchi M, Maehara Y, Kurega D, et al. Risk factors which predict pattern of recurrence after curative surgery for patients with advanced gastric cancer. Surg Oncol. 1992; 1: 341-346.
12. Nakamura K, Ueyama T, Yao T, Xuang ZK, Ambe K, Adachi Y, Yakeishi Y, Matsukuma A, Enjoji M. Pathology and prognosis of gastric carcinoma. Findings in 10,000 patients who underwent primary gastrectomy. Cancer 1992; 70: 1030-1037.
13. Pinheiro DR, Ferrero WAS, Barros MBL, Araújo MD, Rodrigues-Antunes S, Borges BN. Perspectives on new biomarkers in gastric cancer: Diagnostic and prognostic applications. World J Gastroenterol 2014; 20(33): 11574-11585.
14. Rovioo F, Marelli D, Manzoni G, Morgagni P, Di Leo A, Saragoni L, De Stefano A. Prospective study of peritoneal recurrence after curative surgery for gastric cancer. Br J Surg 2003; 90: 1113-1119.
15. Shah MA, Kelsen DP. Gastric Cancer: A Primer on the Epidemiology and Biology of the Disease and an Overview of the Medical Management of Advanced Disease. JNCNN 2010;8:347-447.
16. Suzuki T, Ochiai T, Hayashi H, et al. Peritoneal lavage cytology findings as prognostic factor for gastric cancer. Sem Surg Oncol 1999; 17: 103-117.
17. Tsutsumi S, Asao T, Shimura T, Mochiki E, Kato R, Kuwano H. A novel rapid colorimetric assay of carcinoembryonic antigen levels in the abdominal cavity to detect peritoneal micrometastasis during gastric cancer surgery. Cancer Lett 2003; 1992; 341-346.
18. Wanebo HJ, Kennedy BJ, Chmiel J, Steele G Jr, Winchester D, Osteen R. Cancer of the stomach: a patient care study by the American College of Surgeons. Ann Surg 1993; 218: 583-592.
19. Wang JY, Lin SR, Lu CY, Chen CC, Wu DC, Chai CY, Chen FM, Hsieh JS, Huang TJ. Gastric cancer cell detection in peritoneal lavage: RT-PCR for carcinoembryonic antigen transcripts versus the combined cytology and carcinoembryonic antigen determination in predicting peritoneal carcinoembryonic antigen levels. Cancer Lett 2000; 149: 17-21.
20. Watanabe T, Yamaoka Y, Kato T, Kito T. Prospective staging of gastric carcinoma. A comparison between the UICC stage classification and the 12th edition of the Japanese General Rules for Gastric Cancer Study. Scand J Gastroenterol 1996;31: 476-480.
21. Xiao Y, Ziang J, He X, Ji J, Wang G. Diagnostic values of carcinoembryonic antigen in predicting peritoneal recurrence after curative resection of gastric cancer: meta-analysis. J R Med Sci (2014) 183:557–564. DOI 10.1007/s11845-013-1051-6
22. Yamamoto M, Yoshinaga K, Matsuyama A, Tsutsui S, Ishida T, CEA/CA72-4 levels in peritoneal lavage fluid are predictive factors in patients with gastric carcinoma. J Cancer Res Clin Oncol 2014, (140):607–612. DOI 10.1007/s00432-014-1601-y.
23. Yoo CH, Noh SH, Shin DW, Choi SH, Min JS. Recurrence following curative resection for gastric carcinoma. Br J Surg 2000; 87: 236-242.